
News|Slideshows|July 8, 2026
7 Drugs Approved for Primary Care: Q2 2026
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.
Advertisement
Advertisement
The FDA approved several new or expanded treatment options during the second quarter of 2026 with direct implications for conditions commonly managed or identified in primary care, including obesity, hypertension, diabetes, acne, urinary tract infection, HIV-1 infection, and COVID-19 exposure. The approvals include first-in-class or first-in-category agents, new combination therapies, and options that may affect prescribing conversations, referral decisions, and patient counseling in routine clinical practice.
Related to this article

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.

Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.

Rotavirus vaccine uptake declines under shared clinical decision-making could add up to 4500 infant hospitalizations per birth cohort, a new model projects.

ObesityWeek 2026: Once-weekly semaglutide reduced BMI by 13.5% vs a 2.7% gain with placebo at 68 weeks in children 6 to <12 years with obesity.

The FDA approved at-home dexmedetomidine film for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
Advertisement
Advertisement

